Last reviewed · How we verify

Magnesium Sulfate In Dextrose 5% In Plastic Container — Competitive Intelligence Brief

Magnesium Sulfate In Dextrose 5% In Plastic Container (Magnesium Sulfate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant.

marketed Anticonvulsant Nicotinic acetylcholine receptor Small molecule Live · refreshed every 30 min

Target snapshot

Magnesium Sulfate In Dextrose 5% In Plastic Container (Magnesium Sulfate) — Pfizer Inc.. Magnesium Sulfate blocks neuromuscular transmission and decreases acetylcholine levels, leading to vasodilation and a depressant effect on the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Magnesium Sulfate In Dextrose 5% In Plastic Container TARGET Magnesium Sulfate Pfizer Inc. marketed Anticonvulsant Nicotinic acetylcholine receptor
Succinylcholine Chloride SUXAMETHONIUM Novartis marketed Depolarizing Neuromuscular Blocker Muscle-type nicotinic acetylcholine receptor 1952-01-01
Varenicline Pill Varenicline Pill National Institute on Drug Abuse (NIDA) marketed Nicotinic receptor partial agonist Alpha-4 beta-2 nicotinic acetylcholine receptor
Oxantel Pamoate Oxantel Pamoate Swiss Tropical & Public Health Institute marketed Anthelmintic Nicotinic acetylcholine receptors (nematode-specific)
Varenicline (Champix) Varenicline (Champix) University of British Columbia marketed Nicotinic receptor partial agonist Alpha-4 beta-2 nicotinic acetylcholine receptor
Standard Duration Varenicline Standard Duration Varenicline University of Wisconsin, Madison marketed Nicotinic receptor partial agonist Alpha-4 beta-2 nicotinic acetylcholine receptor
Varenicline (VAR) Varenicline (VAR) University of Oklahoma marketed Nicotinic receptor partial agonist Alpha-4 beta-2 nicotinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant class)

  1. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2 drugs in this class
  2. Ajou University School of Medicine · 1 drug in this class
  3. CAMC Health System · 1 drug in this class
  4. GlaxoSmithKline · 1 drug in this class
  5. Hospital Universitari de Bellvitge · 1 drug in this class
  6. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Magnesium Sulfate In Dextrose 5% In Plastic Container — Competitive Intelligence Brief. https://druglandscape.com/ci/magnesium-sulfate-in-dextrose-5-in-plastic-container. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: